The Royal London Hospital

London WC1N 3HR

5 studies enrolling now · 24 studies all time

What they study most

Acute Ischemic Stroke, Brain Injuries, Chronic Kidney Disease, Chronic Spontaneous Urticaria, DNA Virus Infections, Digestive System Diseases, Focal Epilepsy, Granulomatosis With Polyangiitis (Wegener's) (GPA), Hemophilia A, Hepatitis, Hepatitis B, Hepatitis B, Chronic

Studies at this site

• PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease — Recruiting now
• Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis — Recruiting now
• PS-002 for the Treatment of IgA Nephropathy in Adults — Recruiting now
• Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD). — Recruiting now
• Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy — Running, not enrolling
• ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial — Stopped early
• The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial — Stopped early
• Long-term Safety and Tolerability of BHV-7000 — Enrolling by invitation
• A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) — Running, not enrolling
• A Novel Wearable Digital Biomarker for Detecting Changes in Multiple Sclerosis (MS) Condition — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis — Running, not enrolling
• A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera — Running, not enrolling
• EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin) — Completed
• Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies — Stopped early
• Efficacy and Safety Study of Intravenous Progesterone in Patients With Severe Traumatic Brain Injury — Completed
• EndovaSCular TreAtment to imProve outcomEs for Medium Vessel Occlusions (ESCAPE-MeVO Trial) — Running, not enrolling
• Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ — Completed
• A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors — Completed
• Study Evaluating CERAMENT™|G in Open Diaphyseal Tibial Fractures — Completed
• Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD) — Completed
• Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis — Completed
• Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH) — Stopped early
• Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial — Stopped early
• Epidemiological Study in Children and Adolescents With Chronic Hepatitis B — Completed